Michael Mikhail
Medical Oncology · Malvern, PANPI 1043384035
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,428 and has fallen 83.5% since, to $236 in 2025. That places this record below the midpoint for medical oncology clinicians in PA, where the typical reported total is $2,595.
Across 124 payments — averaging $29.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$479
- Pharmacyclics LLC, An Abbvie Company$410
- Sanofi$367
- AstraZeneca$324
- Bristol Myers Squibb$246
- Caris MPI, Inc.$180
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,34693%
- Education$2707%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 17 | $479 |
| Pharmacyclics LLC, An Abbvie Company | 12 | $410 |
| Sanofi | 4 | $367 |
| AstraZeneca | 14 | $324 |
| Bristol Myers Squibb | 11 | $246 |
| Caris MPI, Inc. | 3 | $180 |
| Servier Pharmaceuticals LLC | 4 | $159 |
| Seagen Inc. | 2 | $138 |
| Akcea Therapeutics, Inc. | 2 | $132 |
| GSK | 1 | $125 |
| Johnson & Johnson | 5 | $119 |
| Genentech USA, Inc. | 6 | $102 |
| Merck | 5 | $67 |
| Gilead(2 entities) | 4 | $62 |
| Adaptive Biotechnologies Corporation | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| Novartis | 3 | $51 |
| Amgen | 3 | $49 |
| Daiichi Sankyo Inc. | 1 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $41 |
| Eisai Inc. | 2 | $36 |
| EMD Serono, Inc. | 1 | $32 |
| Stemline Therapeutics Inc. | 2 | $32 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| Tesaro, Inc. | 1 | $31 |
| Ipsen Biopharmaceuticals, Inc | 1 | $30 |
| Pfizer | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 2 | $25 |
| Verastem, Inc. | 1 | $22 |
| Mylan Institutional Inc. | 1 | $17 |
| Foundation Medicine, Inc. | 1 | $16 |
| Teleflex LLC | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Taiho Oncology, Inc. | 1 | $13 |
| Aurobindo Pharma USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,617 in reported general payments places this provider in the 50th percentile of 238 medical oncology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 11 | $57,661 |
| Anastrozole | 16 | $1,013 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Malvern
- Carl JunePhiladelphia$9M
- Adam BrufskyPittsburgh$1.3M
- Sramila AithalBensalem$682K
- Shayma KazmiPhiladelphia$619K
- Deric SaviorWynnewood$343K
- Marcia BrosePhiladelphia$260K
- Adam CohenPhiladelphia$239K
- Daniel HallerPhiladelphia$227K
- Edith MitchellPhiladelphia$220K
- Elizabeth PlimackPhiladelphia$190K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.